Eureka Therapeutics
Biotechnology, Emeryville, California, United States, 51-200 Employees
Phone Number: 51********
Who is EUREKA THERAPEUTICS
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer. Utilizing our ant...
Read More
-
Headquarters: Emeryville, California, United States
-
Date Founded: 2006
-
Employees: 51-200
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 7299
|
NAICS Code: 812199 |
Show More
Does something look wrong? Fix it. | View contact records from EUREKA THERAPEUTICS
Eureka Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Eureka Therapeutics
Answer: Eureka Therapeutics's headquarters are located at Emeryville, California, United States
Answer: Eureka Therapeutics's phone number is 51********
Answer: Eureka Therapeutics's official website is https://eurekatherapeutics.com
Answer: Eureka Therapeutics's revenue is $25 Million to $50 Million
Answer: Eureka Therapeutics's SIC: 7299
Answer: Eureka Therapeutics's NAICS: 812199
Answer: Eureka Therapeutics has 51-200 employees
Answer: Eureka Therapeutics is in Biotechnology
Answer: Eureka Therapeutics contact info: Phone number: 51******** Website: https://eurekatherapeutics.com
Answer: Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer. Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage. Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month